During the recent session, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s traded shares were 1.0 million, with the beta value of the company hitting 1.06. At the last check today, the stock’s price was $0.78, reflecting an intraday loss of -5.50% or -$0.04. The 52-week high for the LXRX share is $3.73, that puts it down -378.21 from that peak though still a striking 20.51% gain since the share price plummeted to a 52-week low of $0.62. The company’s market capitalization is $280.88M, and the average intraday trading volume over the past 10 days was 4.69 million shares, and the average trade volume was 3.72 million shares over the past three months.
Lexicon Pharmaceuticals Inc (LXRX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.67. LXRX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information
Lexicon Pharmaceuticals Inc (LXRX) registered a -5.50% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -5.50% in intraday trading to $0.78, hitting a weekly high. The stock’s 5-day price performance is 10.20%, and it has moved by -28.72% in 30 days. Based on these gigs, the overall price performance for the year is -34.15%. The short interest in Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) is 31.53 million shares and it means that shorts have 7.06 day(s) to cover.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 87.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $6 respectively. As a result, LXRX is trading at a discount of -669.23% off the target high and -669.23% off the low.
Lexicon Pharmaceuticals Inc (LXRX) estimates and forecasts
Statistics show that Lexicon Pharmaceuticals Inc has underperformed its competitors in share price, compared to the industry in which it operates. Lexicon Pharmaceuticals Inc (LXRX) shares have gone down -57.54% during the last six months, with a year-to-date growth rate less than the industry average at 16.46% against 17.10.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 6.80%. While earnings are projected to return 14.05% in 2024.
LXRX Dividends
Lexicon Pharmaceuticals Inc is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s Major holders
Lexicon Pharmaceuticals Inc insiders own 1.15% of total outstanding shares while institutional holders control 83.11%, with the float percentage being 84.07%. ARTAL GROUP S.A. is the largest shareholder of the company, while 186.0 institutions own stock in it. As of 2024-06-30, the company held over 175.1 million shares (or 71.3555% of all shares), a total value of $294.17 million in shares.
The next largest institutional holding, with 38.69 million shares, is of FMR LLC’s that is approximately 15.7656% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $64.99 million.
Also, the Mutual Funds coming in first place with the largest holdings of Lexicon Pharmaceuticals Inc (LXRX) shares are Fidelity Growth Company Fund and Fidelity Growth Company K6 Fund. Data provided on Oct 31, 2024 indicates that Fidelity Growth Company Fund owns about 17.25 shares. This amounts to just over 4.77 percent of the company’s overall shares, with a $13.08 million market value. The same data shows that the other fund manager holds slightly less at 5.57, or about 1.54% of the stock, which is worth about $4.22 million.
